MedTrace Logo

The Use of Allogenic Platelet Rich Plasma for the Treatment of Diabetic Foot Ulcer

NCT02972528 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-08-28

No results posted yet for this study

Summary

Allogenic defibrinated platelet rich plasma lysate will be injected in patients diagnosed with Diabetic Foot Ulcer (DFU).

Conditions

  • Diabetic Foot Ulcer

Interventions

BIOLOGICAL

Platelet Lysate

Direct injection of allogenic Platelet Lysate

BIOLOGICAL

Platelet Poor Plasma

Direct injection of allogenic Platelet Poor Plasma

Sponsors & Collaborators

  • Hanan Jafar

    lead OTHER

Principal Investigators

  • Abdallah Awidi, MD · Cell Therapy Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-03
Primary Completion
2020-02-29
Completion
2020-09-30

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02972528 on ClinicalTrials.gov